FilingReader Intelligence
Consun Pharmaceutical reports 24% revenue growth to RMB1.57bn
August 19, 2025 at 04:20 AM UTC•By FilingReader AI
Consun Pharmaceutical Group reported revenue of RMB1.57 billion for the six months to June 30, up 23.7% year-on-year. Profit attributable to shareholders rose 24.6% to RMB498 million.
The company declared an interim dividend of HK$0.33 per share. Growth was driven by increased sales of kidney medicines and medical contrast medium.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1681•Hong Kong Exchange
News Alerts
Get instant email alerts when Consun Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime